Lars Fruergaard Jørgensen, Novo Nordisk CEO, at EUBIO21
February 2, 2022 09:53 AM EST
Pharma

No­vo surges on up­beat Q4 re­view and a move to pro­duce We­govy in-house. But charge of in­sulin price ma­nip­u­la­tion lingers

John Carroll

Editor & Founder

No­vo Nordisk shares $NO­VO surged close to 3% on Wednes­day morn­ing as ris­ing prof­its, a key beat on the num­bers and ev­i­dence that the phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

At least sev­en drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions 

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times